Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4400-4418

  Tremblay, Martin R ^a   Lescarbeau, André ^a   Grogan, Michael J ^a   Tan, Eddy ^a   Lin, Grace ^a   Austad, Brian C ^a   Yu, Lin Chen ^a   Behnke, Mark L ^a   Nair, Somarajan J ^a   Hagel, Margit ^a   White, Kerry ^a   Conley, James ^a   Manna, Joseph D ^a   Alvarez Diez, Teresa M ^a   Hoyt, Jennifer ^a   Woodward, Caroline N ^a   Sydor, Jens R ^a   Pink, Melissa ^a   MacDougall, John ^a   Campbell, Matthew J ^a   Cushing, Jill ^a   Ferguson, Jeanne ^a   Curtis, Michael S ^a   McGovern, Karen ^a   Read, Margaret A ^a   Palombella, Vito J ^a   Adams, Julian ^a   Castro, Alfredo C ^a   more..

^a Infinity Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPAMINE; CYCLOPAMINE DERIVATIVE; IPI 269609; IPI 926; SONIC HEDGEHOG PROTEIN; SONIC HEDGEHOG PROTEIN ANTAGONIST; UNCLASSIFIED DRUG; VERATRUM ALKALOID;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANCER INHIBITION; CANCER THERAPY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MONKEY; MOUSE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR REGRESSION; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; DRUG DISCOVERY; HEDGEHOG PROTEINS; HUMANS; LIVER; MEDULLOBLASTOMA; MICROSOMES; SIGNAL TRANSDUCTION; STEREOISOMERISM; VERATRUM ALKALOIDS;

EID: 67650723106     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900305z     Document Type: Article

References (62)

1. Ruiz i Altaba, A.; Sanchez, M. P.; Dahmane, N. Gli and Hedgehog in cancer: tumours, embryos and stem cells. Nat. Rev. Cancer 2002, 2, 361-372.
2. Lum, L.; Beachy, P. A. The Hedgehog response network: sensors, switches, and routers. Science 2004, 304, 1755-1759.
3. di Magliano, M. P.; Hebrok, M. Hedgehog signalling in cancer formation and maintenance. Nat. Rev. Cancer 2003, 3, 903-911.
4. Beachy, P. A.; Karhadkar, S. S.; Berman, D. M. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004, 432, 324-331.
5. Ruiz i Altaba, A. Hedgehog-Gli Signaling in Human Disease; Landes Bioscience/Eurakah.com: Georgetown, TX, 2006; p 226.
6. Bale, A. E.; Yu, K.-p. The hedgehog pathway and basal cell carcinomas. Hum. Mol. Genet. 2001, 10, 757-762.
7. Dahmane, N.; Lee, J.; Robins, P.; Heller, P.; Ruiz i Altaba, A. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997, 389, 876-881.
8. Hutchin, M. E.; Kariapper, M. S. T.; Gratchtchouk, M.; Wang, A.; Wei, L.; Cummings, D.; Liu, J.; Michael, L. R.; Glick, A.; Dlugosz, A. A. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2004, 19, 214-224.
9. Kubo, M.; Nakamura, M.; Tasaki, A.; Yamanaka, N.; Nakashima, H.; Nomura, M.; Kuroki, S.; Katano, M. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res. 2004, 64, 6071-6074.
10. Berman, D. M.; Karhadkar, S. S.; Maitra, A.; Montes de Oca, R.; Gerstenblith, M. R.; Briggs, K.; Parker, A. R.; Shimada, Y.; Eshleman, J. R.; Watkins, D. N.; Beachy, P. A. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumors. Nature 2003, 425, 846-851.
11. Goodrich, L. V.; Scott, M. P. Hedgehog and Patched in neural development and disease. Neuron 1998, 21, 1243-1257.
12. Thayer, S. P.; diMagliano, M. P.; Heiser, P. W.; Nielsen, C. M.; Roberts, D. J.; Lauwers, G. Y.; Qi, Y. P.; Gysin, S.; Fernandez-del Castillo, C.; Yajnik, V.; Antoniu, B.; McMahon, M.; Warshaw, A. L.; Hebrok, M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425, 851-856.
13. Karhadkar, S. S.; Bova, G. S.; Abdallah, N.; Dhara, S.; Gardner, D.; Maitra, A.; Isaacs, J. T.; Berman, D. M.; Beachy, P. A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431, 707-712.
14. Watkins, D. N.; Berman, D. M.; Burkholder, S. G.; Wang, B.; Beachy, P. A.; Baylin, S. B. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003, 422, 313-317.
15. Rubin, L. L; de Sauvage, F. J. Target the hedgehog pathway in cancer. Nat. Rev Cancer 2006, 5, 1026-1033.
16. Frank-Kamenetsky, M.; Zhang, X. M.; Bottega, S.; Guicherit, O.; Wichterle, H.; Dudek, H.; Bumcrot, D.; Wang, F. Y.; Jones, S.; Shulok, J.; Rubin, L. L.; Porter, J. A. Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J. Biol. 2002, 1, 10.1-10.19.
17. Chen, J. K.; Taipale, J.; Young, K. E.; Maiti, T.; Beachy, P. A. Small molecule modulation of Smoothened activity. Proc. Natl Acad. Sci. U.S.A. 2002, 99, 14071-14076.
18. Bijlsma, M. F.; Spek, C. A.; Zivkovic, D.; van de Water, S.; Rezaee, F.; Peppelenbosch, M. P. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol. 2006, 4, 1397-1410.
19. Remsberg, J. R.; Lou, J.; Tarasov, S. G.; Dean, M.; Tarasova, N. I. Structural analogues of Smoothened intracellular loops as potent inhibitors of hedgehog pathway and cancer cell growth. J. Med. Chem. 2007, 50, 4534-4538.
20. Brunton, S. A.; Stibbard, J. H. A.; Rubin, L. L.; Kruse, L. I.; Guicherit, O. M.; Boyd, E. A.; Price, S. Potent inhibitors of the hedgehog signaling pathway. J. Med. Chem. 2008, 51, 1108-1110.
21. Peukert, S.; Jain, R.; Geisser, A.; Sun, Y.; Zhang, R.; Bourret, A.; Carlson, A.; DaSilva, J.; Ramamurthy, A.; Kelleher, J. F. Identification and structure-activity relationships of ortho-biphenyl carboxamides as potent Smoothened antagonists inhibiting the Hedgehog signaling pathway. Bioorg. Med. Chem. Lett. 2009, 19, 328-331.
22. Lauth, M.; Bergstroem, A.; Shimokawa, T.; Toftgard, R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 8455-8460.
23. Lee, J.; Wu, X.; diMagliano, M. P.; Peters, E. C.; Wang, Y.; Hong, J.; Hebrok, M.; Ding, S.; Cho, C. Y.; Schultz, P. G. A Small-molecule antagonist of the Hedgehog signaling pathway. ChemBioChem 2007, 8, 1916-1919.
24. Arai, M. A.; Tateno, C.; Hosoya, T.; Koyano, T.; Kowithayakorn, T.; Ishibashi, M. Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana. Bioorg. Med. Chem. 2008, 16, 9420-9424.
25. Stanton, B. Z.; Peng, L. F.; Maloof, N.; Nakai, K.; Wang, X.; Duffner, J. L.; Taveras, K. M.; Hyman, J. M.; Lee, S. W.; Koehler, A. N.; Chen, J. K.; Fox, J. L.; Mandinova, A.; Schreiber, S. L. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat. Chem. Biol. 2009, 5, 154-156.
26. Von Hoff, D. D.; Rudin, C. M.; LoRusso, P. M.; Borad, M. J.; Korn, R. L.; Heath, E. I.; Yauch, R.; Darbonne, W. C.; Kadel, E. E., III; Zerivitz, K. L.; Nelson, L. E.; Mackey, H.; Marsters, J. C., Jr.; de Sauvage, F. J.; Low, J. A. Efficacy Data of GDC-0449, a Systemic Hedgehog Pathway Antagonist, in a First-in-Human, First-in-Class Phase I Study with Locally Advanced, Multifocal or Metastatic Basal Cell Carcinoma Patients. Presented at the AACR Annual Meeting, San Diego, CA, 2008.
27. A Phase 1 Study of BMS-833923 (XL139) Is Subjects with Advanced of Metastatic Cancer. http://clinicaltrial.gov/ct2/show/NCT00670189.
28. Dose Finding and Safety of Oral LDE225 in Patients with Advanced Solid Tumors. http://clinicaltrials.gov/ct2/show/NCT00880308?term=LDE-225&rank=1.
29. A Phase 1 Study of IPI-926 in Patients with Advanced and/or Metastatic Solid Tumor Malignancies http://clinicaltrial.gov/ct2/show/NCT00761696.
30. Keeler, R. F. Teratogenic compounds of Veratrum californicum (Durand)-IV. First isolation of veratramine and alkaloid Q and a reliable method for isolation of cyclopamine. Phytochemistry 1968, 7, 303-306.
31. Keeler, R. F. Teratogenic compounds of Veratrum californicum (Durand)-VI. The structure of cyclopamine. Phytochemistry 1969, 8, 223-225.
32. Keeler, R. F.; Binns, W. Teratogenic compounds of Veratrum californicum (Durand)-V. Comparison of cyclopian effects of steroidal alkaloids from the plant and structurally related compounds from other sources. Teratology 1968, 1, 5-10.
33. Chen, J. K.; Taipale, J.; Cooper, M. K.; Beachy, P. A. Inhibition of hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002, 16, 2743-2748.
34. Berman, D. M.; Karhadkar, S. S.; Hallahan, A. R.; Pritchard, J. I.; Eberhart, C. G.; Watkins, D. N.; Chen, J. K.; Cooper, M. K.; Taipale, J.; Olson, J. M.; Beachy, P. A. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002, 297, 1559-1561.
35. Sanchez, P.; Ruiz i Altaba, A. In vivo inhibition of endogenous brain tumors through systemic interference of Hedgehog signaling in mice. Mech. Dev. 2005, 122, 223-230.
36. Sanchez, P.; Hernandez, A. M.; Stecca, B.; Kahler, A. J.; DeGueme, A. M.; Barrett, A.; Beyna, M.; Datta, M. W.; Datta, S.; Ruiz i Altaba, A. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 12561-12566.
37. Sheng, T.; Li, C.; Zhang, X.; Chi, S.; He, N.; Chen, K.; McCormick, F.; Gatalica, Z.; Xie, J. Activation of the hedgehog pathway in advanced prostate cancer. Mol. Cancer 2004, 3, 29-42.
38. Zhang, J.; Garrossian, M.; Gardner, D.; Garrossian, A.; Chang, Y.-T.; Kim, Y. K.; Chang, C. W. T. Synthesis and anticancer activity studies of cyclopamine derivatives. Bioorg. Med. Chem. Lett. 2008, 18, 1359-1363.
39. Kumar, S. K.; Roy, I.; Anchoori, R. K.; Fazli, S.; Maitra, A.; Beachy, P. A.; Khan, S. R. Targeted inhibition of Hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. Bioorg. Med. Chem. 2008, 16, 2764-2768.
40. Tremblay, M. R.; Nevalainen, M.; Nair, S. J.; Porter, J. R.; Castro, A. C.; Behnke, M. L.; Yu, L.-C.; Hagel, M.; White, K.; Faia, K.; Grenier, L.; Campbell, M. J.; Cushing, J.; Woodward, C. N.; Hoyt, J.; Foley, M. A.; Read, M. A.; Sydor, J. R.; Tong, J. K.; Palombella, V. J.; McGovern, K.; Adams, J. Semi-synthetic cyclopamine analogues as potent and orally bioavailable Hedgehog pathway antagonists. J. Med. Chem. 2008, 51, 6646-6649.
41. Feldmann, G.; Fendrich, V.; McGovern, K.; Bedja, D.; Bisht, S.; Alvarez, H.; Koorstra, J.-B. M.; Habbe, N.; Karikari, C.; Mullendore, M.; Gabrielson, K. L.; Sharma, R.; Matsui, W.; Maitra, A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 2008, 7, 2725-2735.
42. McGovern, K. J.; Pien, C. S.; Wright, J. L. Dosing Regimen for the Treatment of Cancer. WO2007123511, November 1, 2007.
43. Manna, J. D.; Alvarez-Diez, T. M.; Grogan, M. J.; Porter, J. R.; Tremblay, M. R.; Castro, A. C.; Sydor, J. R. Metabolite Identification of IPI-609, a Novel and Potent Inhibitor of the Hedgehog Pathway, in Different Species. Presented at the ASMS Conference, Denver, CO, June 1-5, 2008.
44. Masamune, T.; Sato, N.; Kobayashi, K.; Yamazaki, I.; Mori, Y. Syntheses and NMR spectra of 22,27-imino-17,23-oxidojervane derivatives. Tetrahedron 1967, 23, 1591-1612.
45. Tsuji, N.; Suzuki, J.; Shiota, M.; Takahashi, I.; Nishimura, S. Highly stereoselective hydrogenation of 3-oxo-4-ene and -1,4-diene steroids to 5β-compounds with palladium catalyst. J. Org. Chem. 1980, 45, 2729-2731.
46. Dwyer, J. R.; Sever, N.; Carlson, M.; Nelson, S. F.; Beachy, P. A.; Parhami, F. Oxysterols are novel activators of the Hedgehog signaling pathway in pluripotent mesenchymal cells. J. Biol. Chem. 2007, 282, 8959-8968.
47. Clinton, R. O.; Clarke, R. L.; Stonner, F. W.; Manson, A. J.; Jennings, K. F.; Phillips, D. K. Steroidal heterocycles. VI. Formylation of A/B-cis 3-ketosteroids. Preparation of 5β-steroidal [3,2-c]pyrazoles. J. Org. Chem. 1962, 27, 2800-2807.
48. Holton, P. G.; Necoechea, E. Steroids. CLXXV. Further steroidal anabolic agents. J. Med. Chem. 1962, 5, 1352-1357.
49. Mrozik, H.; Buchschacher, P.; Hannah, J.; Fried, J. H. Heterocyclic steroids in the antiinflammatory series. J. Med. Chem. 1964, 7, 584-589.
50. Ohta, G.; Takegoshi, T.; Ueno, K.; Shimizu, M. Investigations on steroids. XI. Synthesis of steroidal oxazole, imidazole, and triazole. Chem. Pharm. Bull. 1965, 13, 1445-1459.
51. Marchetti, E.; Donini, P. The synthesis of some isoxazole derivatives of androstane. Chim. Ital. 1961, 91, 1133-1141.
52. Bakshi, R. K.; Patel, G. F.; Rasmusson, G. H.; Baginsky, W. F.; Cimis, G.; Ellsworth, K.; Chang, B.; Bull, H.; Tolman, R. L.; Harris, G. S. 4,7β-Dimethyl-4-azacholestan-3-one (MK-386) and related 4-azasteroids as selective inhibitors of human type 1 5α-reductase. J. Med. Chem. 1994, 37, 3871-3874.
53. Rasmusson, G. H.; Reynolds, G. F.; Utne, T.; Jobson, R. B.; Primka, R. L.; Berman, C.; Brooks, J. R. Azasteroids as inhibitors of rat prostatic 5α-reductase. J. Med. Chem. 1984, 27, 1690-1701.
54. Mazur, R. Azasteroids. III. 3-Aza-A-homo androgens. J. Org. Chem. 1963, 28, 248-250.
55. Shroff, A. P.; Harper, C. H. 3-Aza-A-homoandrostenes. J. Med. Chem. 1969, 12, 190-191.
56. Briggs, K. J.; Corcoran-Schwartz, I. M.; Zhang, W.; Harcke, T.; Devereux, W. L.; Baylin, S. B.; Eberhart, C. G.; Watkins, D. N. Cooperation between the Hic1 and Ptc1 tumor suppressors in medulloblastoma. Gene Dev. 2008, 22, 770-785.
57. Sasai, K.; Romer, J. T.; Lee, Y.; Finkelstein, D.; Fuller, C.; McKinnon, P. J.; Curran, T. Shh pathway activity is downregulated in cultured medulloblastoma cells: implications for preclinical studies. Cancer Res. 2006, 66, 4215-4222.
58. Vestergaard, J.; Pedersen Mikkel, W.; Pedersen, N.; Ensinger, C.; Tumer, Z.; Tommerup, N.; Poulsen Hans, S.; Larsen Lars, A. Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer 2006, 52, 281-290.
59. Yauch, R. L.; Gould, S. E.; Scales, S. J.; Tang, T.; Tian, H.; Ahn, C. P.; Marshall, D.; Fu, L.; Januario, T.; Kallop, D.; Nannini-Pepe, M.; Kotkow, K.; Marsters, J. C., Jr.; Rubin, L. L.; DeSauvage, F. J. A paracrine requirement for hedgehog signaling in cancer. Nature 2008, 455, 406-410.
60. Travaglione, V.; Peacock, C. D.; MacDougall, J.; McGovern, K.; Cushing, J.; Yu, L.-C.; Trudeau, M.; Palombella, V.; Adams, J.; Hierman, J.; Rhodes, J.; Devereux, W. L.; Watkins, D. N. A Novel Hh Pathway Inhibitor, IPI-926, Delays Recurrence Post-Chemotherapy in a Primary Human SCLC Xenograft Model. Presented at the Annual Meeting of AACR, San Diego, CA, 2008.
61. Travaglione, V.; Deyneko, I.; Oaks, Z.; Pink, M.; Proctor, J.; Mandley, E.; Gu, L.; Osswalt, M.; Read, M.; Sydor, J.; McGovern, K.; Palombella, V.; MacDougall, J. Activity of IPI-926, a Novel Inhibitor of the HH Pathway, in Subcutaneous and Orthotopically Implanted Xenograft Tumors That Express SHH Ligand. Presented at the EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", Geneva, Switzerland, 2008.
62. Austad, B.; Behnke, M. L.; Castro, A. C.; Charette, A. B.; Grogan, M. J.; Janardanannair, S.; Lescarbeau, A.; Peluso, S.; Tremblay, M. Cyclopamine Analogs. US 2009/0012109 A1, January 8, 2009.